Continuous-infusion simulations in PBPK and QSP models reveal steady-state properties and rate-limiting steps.

Wilhelmus E. A. de Witte (1), Alexander Kulesza (1), Stephan Schaller (1)

(1) ESQlabs GmbH, Saterland, Germany







OOO es alabs

we empower life sciences

# Intro

Many of the currently available model analysis tools have significant limitations as listed in Table 1. [1-3]. Here we explore extensions of the local sensitivity analysis to obtain an extensive, intuitive, and scalable sensitivity analysis for large-scale models.

Table 1: Overview of available model analysis methods

Method	Pros	Cons
Mathematical model analysis	<ul><li>Comprehensive</li><li>Explicit</li><li>assumptions</li></ul>	<ul> <li>Time + skill intensive</li> <li>Only for small models</li> <li>Not easy to interpret</li> </ul>
Global sensitivity analysis	<ul><li>Comprehensive</li><li>Easy to interpret</li></ul>	<ul><li>Only relative parameter contributions</li><li>Sensitive to conditions</li></ul>
Local sensitivity analysis	<ul><li>Easy to interpret</li><li>Allows specific predictions</li></ul>	<ul> <li>Time consuming</li> <li>No combined parameter effects</li> <li>Sensitive to conditions</li> </ul>

# Methods

The analysis toolbox presented here utilizes the standard sensitivity analysis spider plots as present in the esqlabsR package (v5.1.3) and the ospsuite package (v12.0.0) in R (v4.3.1). Simulation models were created using a whole-body Physiologically-Based Pharmacokinetic model (PK-Sim® v11.2) and extended in MoBi® (v11.2) to include TMDD or PD models. The created models were saved as .pkml files and analyzed in R using dedicated R code for the developed analysis toolbox.

# Results

We developed a "repeated local sensitivity analysis spider plot", a first extension of a single spider plot, by repeating the same analysis for various combinations of two other parameters that define relevant scenarios (Figure 1, Figure 4). The next step towards a comprehensive understanding of model behavior was the model modification with a continuous infusion to introduce a steady-state (Figure 1, 3). Finally, the output was normalized for the output of the neighboring compartment to identify the specific sensitivity for a single compartment (Figure 2, 6).

# Conclusion

As pointed out by Gabrielsson and Peletier[4], analyzing a system in a continuous infusion steady-state can provide significant insight into models with multiple nonlinearities, such as TMDD models. Here we provide such an analysis in a numerical sensitivity analysis framework. This framework allows the application of numerical steady-state analyses to large-scale PBPK or QSP models, as illustrated by the whole body PBPK and the PBPK-QSP examples. This analysis can be further normalized to provide insight into steady-state concentration ratios rather than absolute concentrations. Intermediary versions in between a single sensitivity analysis and a repeated normalized steady-state sensitivity analysis can be of additional value, such as the (normalized) repeated sensitivity analysis.

# Acknowledgments

We would like to express our gratitude to Tatiana Zasedateleva for developing the repeated sensitivity analysis scripts and providing the results for Figure 5.

# References

[1] D. Lee, S. Nayak, S.W. Martin, A.C. Heatherington, P. Vicini, F. Hua, J. Thromb. Haemost. 14 (2016) 2430–2445. https://doi.org/10.1111/jth.13515. [2] S. Bakshi, E. de Lange, P. van der Graaf, M. Danhof, L. Peletier, CPT Pharmacomet. Syst. Pharmacol. 5 (2016) 339–351. https://doi.org/10.1002/psp4.12098.

[3] L.A. Peletier, J. Gabrielsson, J. Pharmacokinet. Pharmacodyn. 39 (2012) 429–451. https://doi.org/10.1007/s10928-012-9260-6.
[4] J. Gabrielsson, L.A. Peletier, AAPS J. 19 (2017) 772–786.

https://doi.org/10.1208/s12248-016-0031-y.

#### Application to a default PK-Sim small molecule model





Figure 6: Repeated sensitivity analysis of a small molecule PBPK model with continuous infusion of the drug in the plasma compartment, for various parameter value combinations. The reference value for lipophilicity is 1. For normalization, the Muscle intracellular concentrations were divided by the plasma concentration.

# Continuous-infusion repeated sensitivity analysis for steady-state analysis and model characterization

From local sensitivity analysis to Continuous-Infusion Repeated Sensitivity Analysis (CIRSA)








Figure 1: Repeating a single sensitivity analysis of a minimal 2-compartment model (left panel) for combinations of other parameters gives a Repeated Sensitivity Analysis (RSA, middle panel). Replacing the bolus dose by a continuous infusion and increasing simulation time to ensure steady-state yields a Continuous-Infusion Repeated Sensitivity Analysis (CIRSA, right panel). Reference values for kin, kout, and kel are 1/h.

Continuous-infusion analysis of the two-compartment model reveals two steady-states that are both relevant for bolus dose conditions

Bolus dose central compartment










Figure 2: Normalized Continuous-Infusion Repeated Sensitivity Analysis of a minimal 2-compartment model. Reference values for kin, kout, and kel are 1/h. For normalization, concentrations in the peripheral compartment are divided by concentrations in the central compartment.

## Application to evaluate a PK-Sim model extension









Figure 3: Repeated sensitivity analysis of the default PK-Sim FcRn model (left) and an extended version (right). The reference value for k<sub>ass</sub> FcRn is 0.87 L/umol/min.

#### Application to an integrated MoBi PBPK-TMDD model







Figure 4: Repeated sensitivity analysis of a Tissue TMDD model with a single IV dose of an IgG. The reference value for Kd is 1 nM.

## Application to an integrated MoBi PBPK-QSP model






Figure 5: Continuous-Infusion Repeated Sensitivity Analysis of a QSP model of ACTH/Corticosterone feedback for understanding of its steady-state behaviour. The reference value for the "Corteffect" parameter is 1.







Supporting the open-source development of:

PK-Sim® MoBi® CSP OPEN SYSTEMS

WWW.Open-Systems-Pharmacology.org

Software Suite